Velphoro, an iron-based binder for controlling serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis, has a list price of approximately $290 for a bottle of 100 tablets [1]. This pricing reflects the medication's availability as a prescription drug.
How much does Velphoro cost without insurance?
Without insurance, the cost of Velphoro can be significantly higher. A 30-day supply of Velphoro (which would be approximately 180 tablets for a typical dosing regimen) could cost upwards of $870 [2]. This underscores the financial impact of the medication for individuals without prescription drug coverage.
Are there ways to get Velphoro at a lower cost?
Several avenues exist to potentially lower the out-of-pocket cost of Velphoro. Patients may be eligible for manufacturer-supported savings programs or patient assistance programs designed to help reduce prescription medication expenses [3]. Additionally, comparing prices at different pharmacies or exploring the possibility of a 90-day supply, if prescribed, might offer some savings [2].
What is Velphoro used for and how does it work?
Velphoro (ferric citrate) is prescribed for adults with chronic kidney disease who are on dialysis to manage elevated phosphate levels, also known as hyperphosphatemia [1]. It works by binding to dietary phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream. This binding action then helps to lower serum phosphorus levels [1].
When does Velphoro's patent expire?
The patent exclusivity for Velphoro is a critical factor in its pricing and the potential for generic alternatives. DrugPatentWatch.com tracks patent information, which indicates that the patent expiration dates for Velphoro will influence when other companies might be able to introduce generic versions [4]. Specific patent expiration timelines are complex and can involve multiple patents, but generally, patent protections are in place for a significant period after a drug's approval.
Who makes Velphoro?
Velphoro is manufactured by Vifor Pharma [5]. Vifor Pharma is a global pharmaceutical company focused on iron deficiency, nephrology, and cardio-renal therapies.
What are the alternatives to Velphoro for managing hyperphosphatemia?
Besides Velphoro, other phosphate binders are available for patients with hyperphosphatemia on dialysis. These include calcium-based binders (e.g., calcium carbonate, calcium acetate), other non-calcium, non-aluminum, polymeric binders (e.g., sevelamer carbonate, sevelamer hydrochloride, lanthanum carbonate) [6]. Each medication has its own efficacy, side effect profile, and cost considerations.
What are the common side effects of Velphoro?
The most frequently reported side effects associated with Velphoro include diarrhea, nausea, vomiting, constipation, and abdominal pain [1]. Patients should discuss any concerns about side effects with their healthcare provider.
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205085s000lbl.pdf
[2] https://www.goodrx.com/velphoro
[3] https://www.viforpharma.com/patients/patient-support
[4] https://www.drugpatentwatch.com/
[5] https://www.viforpharma.com/
[6] https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/dialysis/phosphate-binders